Clinical trials: Prostate Hyperplasia
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Benign Prostatic Hyperplasia (BPH)
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Single arm, multi-center prospective clinical trial to determine the safety and effectiveness of the AQUABEAM System in the treatment of benign prostatic hyperplasia (BPH) in men 45 to 80 years of age.
- Trial name
- NCT03191734
- Testing
- AQUABEAM System
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
This is a phase 2 study to evaluate the safety and effectiveness of light-activated talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT00918034
- Testing
- talaporfin sodium, Transurethral illumination with light emitting diodes, Placement
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 21 people
- Sponsor
- Light Sciences Oncology
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hypertrophy
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00449150
- Testing
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg
- Where
- 68 sites in United States, Bulgaria and 2 more
- Volunteers
- 667 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;
Prostate adenoma, also known as benign prostatic hypertrophy or hyperplasia (BPH), involves an increase in the size of the prostate, forming a benign tumor.
- Trial name
- BPH EFFICACY (NCT06601179)
- Testing
- HIFU
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- EDAP TMS S.A.
Prostatic Hyperplasia
Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
Adherence and length of therapy with 5-alpha reductase inhibitor (5ARI) treatment may be associated with improved clinical outcomes of enlarged prostate (EP) as well as lower health care costs.
- Trial name
- NCT01381510
- Testing
- 5-alpha Reductase Inhibitor (5ARI)
- Volunteers
- 54,459 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hypertrophy
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of…
- Trial name
- AEZS-102-Z041 (NCT00670306)
- Testing
- Cetrorelix Pamoate
- Where
- 69 sites in United States, Canada
- Volunteers
- 528 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia
A single-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with commercially approved catheters following prostate resection using the AquaBeam for treatment of LUTS…
- Trial name
- AHA (NCT03125863)
- Testing
- AquaBeam System
- Where
- India
- Volunteers
- 21 people
- Sponsor
- PROCEPT BioRobotics
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Benign Prostatic Hyperplasia
The ProVerum First in Man PROVE Study
A clinical evaluation to assess the safety and performance of the ProVeeTM Urethral Expander System, designed to alleviate the symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT03972371
- Testing
- The ProVee Urethral Expander System
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- ProVerum Medical
Benign Prostatic Hyperplasia
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc.
- Trial name
- NCT03887871
- Testing
- Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.
- Trial name
- MCS-2-TWN-c (NCT01002274)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hyperplasia, Varicocele Grade II
Vivifi's Treatment, BPH Treatment Via Vasculature Anastomosis
The study objective is to evaluate the safety and feasibility of the Vivifi's Treatment. The Vivifi's Treatment presents an innovative approach for addressing benign prostatic hyperplasia (BPH) as well as clinical/subclinical…
- Conditions
- Benign Prostatic Hyperplasia, Varicocele Grade II, Varicocele Grade III
- Trial name
- NCT06424912
- Testing
- Vivifi's Surgical Procedure
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Vivifi Medical
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Butterfly Pivotal Study
A prospective, multicenter, blind randomized (2:1) controlled study comparing the International Prostate Symptom Score (IPSS) of the Active arm to the IPSS of the control arm at the 3 months follow-up and active arm IPSS score…
- Trial name
- NCT05341661
- Testing
- Butterfly Prostatic Retraction Device
- Where
- 3 sites in United States
- Volunteers
- 245 people
- Sponsor
- Butterfly Medical Ltd.
Benign Prostatic Hyperplasia
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
The purpose of this study is to confirm in a larger population in Europe the effectiveness and safety observed with silodosin in previous clinical trials.
- Trial name
- SiRE (NCT01757769)
- Testing
- Silodosin
- Where
- Italy
- Volunteers
- 1,036 people
- Sponsor
- RECORDATI GROUP
Benign Prostatic Hyperplasia (BPH)
Study to Assess the Efficacy of Medi-Tate iTind Device
The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.
- Trial name
- NCT02145208
- Testing
- TIND System
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 81 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Prostatic Hyperplasia
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of…
- Trial name
- NCT02244229
- Testing
- Tamsulosin, Finasteride
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim